News & Perspective

Nov 02, 2001

Nov 02, 2001

Doxycycline, penicillin G procaine already approved for postexposure prophylaxis against anthrax, FDA notes

(CIDRAP News) – The Food and Drug Administration (FDA) published a notice in the Federal Register this week to make clear that doxycycline and penicillin G procaine, along with ciprofloxacin, already are approved for use as postexposure prophylaxis following inhalational exposure to anthrax. The notice also details postexposure dosing regimens for these medications.

Nov 30, 2001

Nov 30, 2001

Acambis wins new contract to supply 155 million doses of smallpox vaccine

Nov 29, 2001 (CIDRAP News) – The US Department of Health and Human Services (HHS) has awarded Acambis Inc. a $428 million contract to produce an additional 155 million doses of smallpox vaccine by the end of 2002, HHS Secretary Tommy G. Thompson announced Wednesday.

Dec 03, 2001

Dec 03, 2001

Study says risk of BSE in US is low, but USDA contemplates more precautions

(CIDRAP News) – A new study commissioned by the US Department of Agriculture (USDA) indicates that the risk of bovine spongiform encephalopathy (BSE) occurring in the United States is extremely low, but USDA officials who released the study said they are considering taking steps to lower the risk further.

Dec 07, 2001

Dec 07, 2001

Rapid tests for environmental anthrax should not be used alone, CDC says

(CIDRAP News) – Rapid tests for detecting anthrax spores on surfaces should not be used alone as the basis for public health or clinical decisions, the Centers for Disease Control and Prevention warned in today's issue of Morbidity and Mortality Weekly Report.

Dec 13, 2001

Dec 13, 2001

House passes $2.9 billion authorization for bioterrorism preparedness

(CIDRAP News) – The US House of Representatives on Wednesday overwhelmingly approved a bill authorizing about $2.9 billion in spending on preparedness for bioterrorism and other public health emergencies.

Dec 19, 2001

Dec 19, 2001

Anthrax vaccine to be offered to postal and Capitol workers

(CIDRAP News) – Because of a small theoretical risk that anthrax spores can hide in the lungs for up to 100 days and grow after antibiotic treatment is stopped, the anthrax vaccine and an extension of antibiotic treatment will be offered to people who may have been exposed in the recent anthrax attacks, federal health officials announced yesterday afternoon.

Dec 21, 2001

Dec 21, 2001

FDA completes inspection of anthrax vaccine plant; company expects approval

Dec 4, 2003 (CIDRAP News) – Thousands of US Customs and Border Protection (CBP) officers will help the Food and Drug Administration (FDA) inspect imported food under an agreement signed yesterday, according to the FDA.

Dec 21, 2001

FDA completes inspection of anthrax vaccine plant; company expects approval

(CIDRAP News) – The Food and Drug Administration (FDA) has completed a new inspection of BioPort Corp., the only US manufacturer of the anthrax vaccine, and a company official is predicting approval of the facility after a few remaining concerns are ironed out.

Jan 02, 2002

Jan 02, 2002

Anthrax vaccine option has few takers so far

Jan 2, 2001 (CIDRAP News) – Aside from Capitol Hill staff members, only 52 of more than 3,500 people who have been offered the anthrax vaccine because of the recent mail attacks have decided to take it, according to the Centers for Disease Control and Prevention (CDC).

Jan 07, 2002

Jan 07, 2002

New nuclear medicine technique shows promise for early diagnosis of anthrax

(CIDRAP News) – A new nuclear medicine technique using a radioisotope-labeled antibody has shown enough promise for early diagnosis of anthrax infection to gain the Food and Drug Administration's approval for a clinical trial, according to a recent report in the Journal of Nuclear Medicine.

Pages

Sort Results

 

Narrow results

by Topic

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»